# Sun Pharmaceutical Industries Ltd (SUNPHARMA)
> Exchange: NSE | Sector: Pharma | ISIN: 

## Price
Current Price: ₹1891.3
Day Change: +0.59%
52W High: ₹1887.1
52W Low: ₹1547.25
Market Cap: ₹4,51,075 Cr

## Valuation
P/E: 41.32
P/B: 5.79
EPS: ₹45.5
Book Value: ₹324.46
Dividend Yield: 0.89%

## Returns
1Y Return: 8.45%

## Profitability
ROE: 0%
ROCE: 25.06%
Debt/Equity: 0.07
Revenue Growth: 13.5%
Profit Growth: 15.7%
EBITDA Margin: 28.21%
Operating Margin: 26.17%

## About
Sun Pharma Inds. is a leading Indian company in the Pharmaceuticals space, listed on the NSE. The company is a key player in the Pharma — Formulations segment with a strong market position and diversified operations.
Sector: Pharma
Industry: Drug Manufacturers - Specialty & Generic
Sub Industry: Pharma — Formulations

## Business Model
Overview: Sun Pharmaceutical Industries Ltd makes money through Core Business, Other Segments, Exports in Pharma — Formulations. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Source: Derived from stock data
Revenue Streams:
- Core Business
- Other Segments
- Exports
Operating Model:
- Develops, manufactures, distributes, or services healthcare products across regulated channels.
- Approvals, product mix, compliance quality, and R&D productivity shape growth.
Business Segments:
- Core Business: 75% of tracked revenue, equal to ₹1,00,585 Cr. | 75% | ₹1,00,585 Cr
- Other Segments: 29% of tracked revenue, equal to ₹38,893 Cr. | 29% | ₹38,893 Cr
- Exports: -4% of tracked revenue, equal to ₹-5,365 Cr. | -4% | ₹-5,365 Cr
Recent Context:
- Announcement: Announcement under Regulation 30 (LODR)-Newspaper Publication
- Announcement: Intimation For Receipt Of Requests For Reclassification Of Shareholder Category
- BSE Filing: Intimation For Receipt Of Requests For Reclassification Of Shareholder Category

## Access
Current tier: anonymous
More history: Register free to see 13 more years.

## Data Freshness
Quote Updated: 2026-05-21T20:00:05.656Z
Price History Updated: 2026-05-17T21:29:50.301Z
Latest Price History Date: 2026-05-17
Technicals Updated: 2026-05-17T21:29:50.301Z
Quant Updated: 2026-05-17T21:29:50.301Z
Sentiment Updated: 2026-05-17T21:29:50.301Z
Financials Status: current
Financials Updated: 2026-05-19T01:13:03.469Z
Financials Last Attempt: 2026-05-19T01:13:03.469Z
Financials Provider Tried: yahoo
Latest P&L Period: FY25
Latest Balance Sheet Period: FY25
Latest Cash Flow Period: FY25

## P&L (FY25)
Revenue: ₹52041.25 Cr
Operating Profit: ₹12581.2 Cr (OPM 24.18%)
Net Profit: ₹10929.04 Cr
Tax: ₹2772.03 Cr

## Annual P&L History
FY25: Rev ₹52041.25Cr | PAT ₹10929.04Cr | OPM 24.18%
FY24: Rev ₹47758.45Cr | PAT ₹9576.38Cr | OPM 21.92%
FY23: Rev ₹43278.87Cr | PAT ₹8473.58Cr | OPM 21.44%

## Balance Sheet (FY25)
Total Assets: ₹92100.58 Cr
Total Liabilities: ₹19614.63 Cr
Borrowings: ₹2362.19 Cr
Cash: ₹10268.77 Cr

## Shareholding
Promoters: 59.1%
FIIs: 24.89%
DIIs: 11.55%
Public: 4.46%

## Board
- Dilip Shantilal Shanghvi, Executive Chairman of the Board
- Aalok Dilip Shanghvi, COO, Head of Global Generics R&D, Business Devp., and Whole Time Director
- Kirti Wardhaman Ganorkar, Managing Director
- Jayashree  Satagopan, Executive VP & CFO
- Dheeraj Prasad Sinha BE, EVP & Chief Information Officer

## Highlights
- Strong revenue growth of 13% CAGR over 5 years
- ROE of 15.0% indicates efficient capital allocation

## Concerns
- Debt-to-equity ratio needs monitoring amid expansion plans
- Promoter holding has seen slight decline in recent quarters

---
Source: rupiya.io/stocks/sunpharma
Disclaimer: For research and education only. Not investment advice.